AU2004271706B2 - Factor IXa specific antibodies displaying factor VIIIa like activity - Google Patents

Factor IXa specific antibodies displaying factor VIIIa like activity Download PDF

Info

Publication number
AU2004271706B2
AU2004271706B2 AU2004271706A AU2004271706A AU2004271706B2 AU 2004271706 B2 AU2004271706 B2 AU 2004271706B2 AU 2004271706 A AU2004271706 A AU 2004271706A AU 2004271706 A AU2004271706 A AU 2004271706A AU 2004271706 B2 AU2004271706 B2 AU 2004271706B2
Authority
AU
Australia
Prior art keywords
antibody
factor
antibodies
fixa
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004271706A
Other languages
English (en)
Other versions
AU2004271706A1 (en
Inventor
Randolf Kerschbaumer
Friedrich Scheiflinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34273861&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2004271706(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2004271706A1 publication Critical patent/AU2004271706A1/en
Application granted granted Critical
Publication of AU2004271706B2 publication Critical patent/AU2004271706B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004271706A 2003-09-12 2004-09-07 Factor IXa specific antibodies displaying factor VIIIa like activity Expired AU2004271706B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/661,366 US7297336B2 (en) 2003-09-12 2003-09-12 Factor IXa specific antibodies displaying factor VIIIa like activity
US10/661,366 2003-09-12
PCT/EP2004/009975 WO2005025615A2 (en) 2003-09-12 2004-09-07 FACTOR IXa SPECIFIC ANTIBODIES DISPLAYING FACTOR VIIIa LIKE ACTIVITY

Publications (2)

Publication Number Publication Date
AU2004271706A1 AU2004271706A1 (en) 2005-03-24
AU2004271706B2 true AU2004271706B2 (en) 2010-09-02

Family

ID=34273861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004271706A Expired AU2004271706B2 (en) 2003-09-12 2004-09-07 Factor IXa specific antibodies displaying factor VIIIa like activity

Country Status (9)

Country Link
US (1) US7297336B2 (enExample)
EP (1) EP1660536B1 (enExample)
JP (1) JP4887148B2 (enExample)
AT (1) ATE419277T1 (enExample)
AU (1) AU2004271706B2 (enExample)
CA (1) CA2538895A1 (enExample)
DE (1) DE602004018788D1 (enExample)
ES (1) ES2320665T3 (enExample)
WO (1) WO2005025615A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
CA2603264C (en) * 2005-04-08 2017-03-21 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
EP1760092A1 (en) * 2005-08-26 2007-03-07 Applied Research Systems ARS Holding N.V. System for screening cells for high expression of a protein of interest
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
KR101962483B1 (ko) 2010-11-17 2019-03-29 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
CA2886326C (en) * 2012-09-28 2021-11-02 Chugai Seiyaku Kabushiki Kaisha Method for evaluating blood coagulation reaction
CN105764922B (zh) 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
WO2015138600A2 (en) * 2014-03-11 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
WO2017110980A1 (ja) 2015-12-25 2017-06-29 中外製薬株式会社 増強された活性を有する抗体及びその改変方法
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
ES3055961T3 (en) 2016-04-28 2026-02-17 Chugai Pharmaceutical Co Ltd Antibody-containing preparation
IL262813B2 (en) * 2016-05-16 2025-12-01 Baxalta GmbH Anti-factor ix padua antibodies
CN109415444B (zh) 2016-07-29 2024-03-01 中外制药株式会社 显示增加的备选fviii辅因子功能活性的双特异性抗体
EP3509637B1 (en) 2016-09-06 2024-11-27 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
AU2017331739A1 (en) * 2016-09-23 2019-03-07 Csl Limited Coagulation factor binding proteins and uses thereof
CN110662770A (zh) * 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
KR20190112747A (ko) 2017-02-01 2019-10-07 노보 노르디스크 에이/에스 응고촉진 항체
EP3603670A4 (en) 2017-03-31 2021-03-10 Public University Corporation Nara Medical University MEDICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF BLOOD CLOG FACTOR IX ANOMALY WITH A MULTI-SPECIFIC ANTIGIBINDING MOLECULAR FUNCTION OF BLOOD CLOTHING FACTOR VIII
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
JP6496095B1 (ja) 2017-09-29 2019-04-03 中外製薬株式会社 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）補因子機能代替活性を有する多重特異性抗原結合分子および当該分子を有効成分として含有する薬学的製剤
TW202600611A (zh) 2017-11-01 2026-01-01 日商中外製藥股份有限公司 生物活性降低之抗體變異體與同功型
CN112513096B (zh) 2018-08-01 2023-08-25 诺和诺德股份有限公司 改进的促凝血抗体
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
CN115052898B (zh) 2020-01-30 2025-09-16 诺和诺德股份有限公司 双特异性因子viii模拟抗体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019992A2 (en) * 1999-09-14 2001-03-22 Baxter Aktiengesellschaft FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT368883B (de) 1980-07-22 1982-11-25 Immuno Ag Verfahren zur herstellung einer neuen blutgerinnungsfoerdernden praeparation auf basis von humanproteinen
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DK0658168T3 (da) 1992-08-27 2001-01-22 Sanquin Bloedvoorziening Antistoffer, som er specifikke for et hæmostatisk protein, anvendelse heraf til isolering af intakt protein, hæmostatiske p
DK128093D0 (da) 1993-11-12 1993-11-12 Novo Nordisk As Hidtil ukendte forbindelser
MA24512A1 (fr) 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
EP1001991A4 (en) 1997-07-03 2005-01-26 Smithkline Beecham Corp CRYSTALLINE STRUCTURES OF FAB ANTI-FACTOR IX FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
KR100900166B1 (ko) * 2001-05-03 2009-06-02 메르크 파텐트 게엠베하 재조합 종양 특이적 항체 및 이들의 용도

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019992A2 (en) * 1999-09-14 2001-03-22 Baxter Aktiengesellschaft FACTOR IX/FACTOR IXa ANTIBODIES AND ANTIBODY DERIVATIV ES

Also Published As

Publication number Publication date
CA2538895A1 (en) 2005-03-24
US7297336B2 (en) 2007-11-20
ATE419277T1 (de) 2009-01-15
DE602004018788D1 (de) 2009-02-12
ES2320665T3 (es) 2009-05-27
EP1660536A2 (en) 2006-05-31
WO2005025615A3 (en) 2005-06-02
WO2005025615A2 (en) 2005-03-24
US20050058640A1 (en) 2005-03-17
JP2007504812A (ja) 2007-03-08
AU2004271706A1 (en) 2005-03-24
EP1660536B1 (en) 2008-12-31
JP4887148B2 (ja) 2012-02-29

Similar Documents

Publication Publication Date Title
US7297336B2 (en) Factor IXa specific antibodies displaying factor VIIIa like activity
JP6944509B2 (ja) Ｉｌ−１８結合分子
JP4313531B2 (ja) 第ＩＸ因子／第ＩＸａ因子の抗体および抗体誘導体
EP2542257B1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
MX2011001351A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular.
TW201536810A (zh) 結合尿激酶纖維蛋白溶酶原活化物之抗體
US10144784B2 (en) Monoclonal antibodies against antithrombin beta
CN114773473A (zh) 抗cd39抗体及其制备方法和用途
US7858089B2 (en) Antibodies binding to the A2 domain of FVIII and inhibiting coagulation activity
US20060177446A1 (en) Polypeptides that bind an anti-tissue factor antibody and uses thereof
Eigenbrot et al. Structural insight into how an anti-idiotypic antibody against D3H44 (anti-tissue factor antibody) restores normal coagulation
AU2022289196A1 (en) Novel antithrombotic antibody
AU2016269554B2 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
KR20230142724A (ko) 인자 XIa 억제제에 대한 항체 및 항원 결합 펩티드및 그의 용도
WO2015004148A1 (en) Biomarker of plasminogen activation system and/or of upar/vn interaction and uses thereof
HK1156635A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 07 SEP 2014 TO 07 APR 2015 IN WHICH TO PAY A RENEWAL FEE HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY A RENEWAL FEE HAS BEEN EXTENDED TO 07 APR 2015 .

PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): BAXTER HEALTHCARE S.A.; BAXTER INTERNATIONAL INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired